Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Shang, L., Dong, S
Otherwise, dispose via our in-store recycling program
10.1016/S0076-6879(10)74012-X 66 ChoiS
It was clinically approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) in 2014 for the treatment of relapsing-remitting multiple sclerosis (MS), showing a significant efficacy over 2 years versus placebo and a favorable benefit-risk profile in two phase-III clinical trials, although with several adverse effects such as nausea, diarrhea, abdominal pain and leukopenia in some patients [282, 283]
NO itself is a source of cytotoxic molecules, and its deleterious effects are enhanced by its ability to concentrate locally around tumor cells and the tumor microenvironment
US$ 25.09
US$ 23.39
US$ 28.89
US$ 25.37
